Axatilimab not checked

Incyte · Syndax Pharmaceuticals · INCA034176 · SNDX-6352

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 1/2 trial completes
Trials
7 active
12 in total · 6 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.”In the company’s words, NCT04710576 on ClinicalTrials.gov
Tested for
Chronic Graft-versus-host-disease (7 trials)
Main trialPhase 3
“This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).”In the company’s words, NCT06263478 on ClinicalTrials.gov
Other names
INCA034176 · Niktimvo · SNDX-6352

Other drugs for Chronic Graft-versus-host-disease

All 17 drugs for Chronic Graft-versus-host-disease

Coming up4

Changes2

Last 90 days

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 6 Aug 2025 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
Phase 3Recruiting 28 Sep 2027 A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Phase 3Active, not recruiting 31 May 2028 A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
Phase 2Recruiting 7 Apr 2023 A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Phase 2Active, not recruiting 1 Oct 2026 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Phase 2Recruiting 31 Jan 2029 A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Phase 1/2Active, not recruiting 6 Jan 2027 A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
Phase 2Terminated 13 Jul 2020 A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
Phase 2Completed 27 Aug 2026 MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Phase 1/2Completed 12 Aug 2022 A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
Phase 1Completed 20 Nov 2020 A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
Phase 1Completed 6 Jun 2025 A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Axatilimab

Following is part of Solo: you see every change to Axatilimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in